ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,870,915 | +62.2% | 541,920 | +128.1% | 0.01% | +50.0% |
| Q2 2023 | $6,703,260 | +1324654.9% | 237,620 | +708.4% | 0.00% | – |
| Q1 2023 | $506 | -21.9% | 29,394 | -8.7% | 0.00% | – |
| Q4 2022 | $648 | -100.0% | 32,186 | -68.0% | 0.00% | -100.0% |
| Q3 2022 | $2,181,000 | +57.6% | 100,672 | +235.6% | 0.00% | 0.0% |
| Q1 2022 | $1,384,000 | -67.7% | 30,000 | -41.1% | 0.00% | -66.7% |
| Q4 2021 | $4,284,000 | +205.3% | 50,966 | +93.3% | 0.00% | +200.0% |
| Q2 2021 | $1,403,000 | -74.8% | 26,368 | -79.4% | 0.00% | -75.0% |
| Q1 2021 | $5,564,000 | – | 128,229 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |